Murali, GanesanMilne, Ginger L.Webb, Corey D.Stewart, Ann B.McMillan, Ryan P.Lyle, Brandon C.Hulver, Matthew W.Saraswathi, Viswanathan2017-10-122017-10-122012-07-29http://hdl.handle.net/10919/79623Fish oil (FO) is a potent anti-inflammatory and lipid-lowering agent. Because inflammation can modulate lipid metabolism and vice versa, we hypothesized that combining FO with cyclooxygenase inhibitors (COXIBs), well-known anti-infl ammatory drugs, can enhance the antiinfl ammatory and lipid-lowering effect of FO. LDLR⁻/⁻ mice were fed a high-fat diet supplemented with 6% olive oil or FO for 12 wk in the presence or absence of indomethacin (Indo, 6 mg/l drinking water). FO reduced plasma total cholesterol by 30% but, in combination with Indo, exerted a greater decrease (44%). The reduction of liver cholesterol ester (CE) and triglycerides (TG) by FO (63% and 41%, respectively) was enhanced by Indo (80% in CE and 64% in TG). FO + Indo greatly increased the expression of genes modulating lipid metabolism and reduced the expression of inflammatory genes compared with control. The mRNA and/or protein expression of pregnane X receptor (PXR) and cytochrome P450 isoforms that alter inflammation and/or lipid metabolism are increased to a greater extent in mice that received FO + Indo. Moreover, the nuclear level of PXR is significantly increased in FO + Indo group. Combining FO with COXIBs may exert their beneficial effects on inflammation and lipid metabolism via PXR and cytochrome P450.application/pdfenIn Copyrightn-3 fatty acidscytochrome P450cholesteroltriglyceridesArticle - Refereedhttps://doi.org/10.1194/jlr.M02984353